Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.…
Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference
Alterity Therapeutics (NASDAQ: ATHE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 1.520 USD on 20 November 2026, down 59.9% over 52 weeks. Its 52-week range is 1.520 USD to 5.890 USD, and it trades at the bottom of that range.
Its market capitalisation is 29.02M USD.
Alterity Therapeutics reports return on equity of -54.8% and revenue down 79.0% year over year.
It holds more cash than debt, a net cash position of 37.12M AUD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.